Genitourinary Cancer | Norton Healthcare

Indication: Genitourinary Cancer

A Phase 3 Randomized, Double-Blind Study of Nivolumab or Placebo in Combination with Docetaxel, in Men with Metastatic Castration-resistant Prostate Cancer (CheckMate 7DX:CHECKpoint pathway and nivolu

Sub-indication: Genitourinary Cancer

Drug Study

Principal Investigator: Joseph Maly, M.D.
Norton Cancer Institute

Sponsor: Bristol-Myers Squibb (BMS)

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.